| 詳細情報 |  |
|---|---|
| 関連リンク |  |
| 探す |  |
論文 (44件)
- Yoshihiko Tasaki, Shuzo Hamamoto, Shimpei Yamashita, Junya Furukawa, Kazutoshi Fujita, Ryotaro Tomida, Makito Miyake, Noriyuki Ito, Hideto Iwamoto, Yoshihisa Mimura, et al. Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study. Frontiers in Immunology. 2025. 15
- Taku Naiki, Aya Naiki-Ito, Akihiro Murakami, Hiroyuki Kato, Yosuke Sugiyama, Tatsuya Kawai, Shinji Kato, Toshiki Etani, Takashi Nagai, Nobuhiko Shimizu, et al. Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance. Prostate cancer. 2025. 2025. 8165686-8165686
- 磯部 輝紀, 内木 拓, 杉山 洋介, 恵谷 俊紀, 清水 伸彦, 権田 将一, 青木 マリア, 森川 敏治, 河合 憲康, 安井 孝周. 転移性尿路上皮癌に対するアベルマブ治療成績の解析. 泌尿器科紀要. 2024. 70. 11. 402-403
- Taku Naiki, Kiyoshi Takahara, Hiromitsu Watanabe, Keita Nakane, Yosuke Sugiyama, Takuya Koie, Ryoichi Shiroki, Hideaki Miyake, Takahiro Yasui. The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer. Japanese journal of clinical oncology. 2024
- 三村 佳久, 内木 拓, 小田切 州広, 惠谷 俊紀, 権田 将一, 清水 伸彦, 青木 マリア, 森川 敏治, 冨田 実里, 田崎 慶彦, et al. 尿路上皮がん患者に対するアナモレリンの有効性と安全性 多施設共同無作為化比較試験. 日本癌治療学会学術集会抄録集. 2024. 62回. O27-5
- Shuzo Hamamoto, Yoshihiko Tasaki, Shimpei Yamashita, Junya Furukawa, Kazutoshi Fujita, Ryotaro Tomida, Makito Miyake, Noriyuki Ito, Hideto Iwamoto, Yosuke Sugiyama, et al. External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma. Frontiers in Oncology. 2024. 14. 1400041-1400041
- Teruki Isobe, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Keitaro Iida, Yusuke Noda, Nobuhiko Shimizu, Maria Aoki, et al. Experience and prognostic analysis with avelumab switch maintenance treatment in metastatic urothelial carcinoma. Oncology. 2024. 1-11
- Shuzo Hamamoto, Yoshihiko Tasaki, Toshiharu Morikawa, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Shoichiro Iwatsuki, Rei Unno, Tomoki Takeda, Takashi Nagai, et al. Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma. Journal of clinical medicine. 2024. 13. 12
- Yoshihiko Tasaki, Nanami Ito, Yoshihisa Mimura, Yosuke Sugiyama, Ryo Ogawa, Takaya Shimura, Motoki Nakamura, Daisuke Kawakita, Shuzo Hamamoto, Takehiro Uemura, et al. Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients. Asia-Pacific journal of clinical oncology. 2024. 20. 4. 515-521
- Toshiharu Morikawa, Taku Naiki, sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Keitaro Iida, Teruki Isobe, Yusuke Noda, Nobuhiko Shimizu, et al. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study. Cancers. 2024. 16. 9
- Keitaro Iida, Taku Naiki, Toshiki Etani, Takashi Nagai, Yosuke Sugiyama, Teruki Isobe, Maria Aoki, Satoshi Nozaki, Yusuke Noda, Nobuhiko Shimizu, et al. Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma. Scientific reports. 2024. 14. 1. 2520-2520
- Yoshihisa Mimura, Taku Naiki, Yosuke Sugiyama, Yoshihiko Tasaki, Kunihiro Odagiri, Toshiki Etani, Takashi Nagai, Moeko Iida, Yuka Kimura, Nanami Ito, et al. Cachexia Index Is a Prognostic Indicator in Patients With Metastatic Urothelial Carcinoma Treated With Systemic Chemotherapy. Cancer diagnosis & prognosis. 2024. 4. 4. 475-481
- Yoshihiko Tasaki, Yosuke Sugiyama, Shuzo Hamamoto, Taku Naiki, Takehiro Uemura, Keisuke Yokota, Daisuke Kawakita, Motoki Nakamura, Ryo Ogawa, Takaya Shimura, et al. Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study. Cancer medicine. 2023
- Taku Naiki, Kiyoshi Takahara, Hiromitsu Watanabe, Keita Nakane, sugiyama, Takuya Koie, Ryoichi Shiroki, Hideaki Miyake, Takahiro Yasui. The Geriatric Nutritional Risk Index Predicts Prognosis in Japanese Patients with LATITUDE High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Multi-Center Study. Cancers. 2023
- Nayuka Matsuyama, Taku Naiki, Shuzo Hamamoto, sugiyama, Yasue Kubota, Takashi Hamakawa, Toshiki Etani, Shoichiro Iwatsuki, Kazumi Taguchi, Yuya Ota, et al. Postoperative Bladder Neck to Pubic Symphysis Ratio Predictive for De Novo Overactive Bladder after Robot-Assisted Radical Prostatectomy. Diagnostics. 2023. 13. 20
- Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Nami Tomiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura, et al. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association. 2023. 30. 10. 866-874
- Nami Tomiyama, Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura, et al. Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association. 2023. 30. 9. 754-761
- Takashi Nagai, Taku Naiki, Yosuke Sugiyama, Toshiki Etani, Maria Aoki, Masakazu Gonda, Toshiharu Morikawa, Keitaro Iida, Nami Tomiyama, Ryosuke Ando, et al. A narrative review of peripheral blood parameters for urothelial carcinoma treated with systemic antitumor drugs. Translational Andrology and Urology. 2023. 12. 5. 790-801
- Yosuke Sugiyama, Taku Naiki, Yoshihiko Tasaki, Yoshihisa Mimura, Toshiki Etani, Yusuke Noda, Satoshi Nozaki, Nobuhiko Shimizu, Rika Banno, Takashi Nagai, et al. GNRI sustainability during one cycle of first-line chemotherapy as a prognostic indicator in patients with metastatic urothelial carcinoma. Oncology. 2023. 101. 4. 224-233
- Yoshihisa Mimura, Yosuke Sugiyama, Taku Naiki, Tomoya Kataoka, Yoshihiko Tasaki, Toshiki Etani, Nami Tomiyama, Nayuka Matsuyama, Kunihiro Odagiri, Kazunori Kimura, et al. A rare case of successful pain control in a prostate cancer patient with bone metastasis undergoing hemodialysis by measuring the serum oxycodone level and using an activity tracker. Current Problems in Cancer: Case Reports. 2022. 7
前のページに戻る
